Trimipramine
Surmontil (trimipramine) is a small molecule pharmaceutical. Trimipramine was first approved as Surmontil on 1982-01-01. It is used to treat depressive disorder and psychotic affective disorders in the USA. The pharmaceutical is active against sodium-dependent serotonin transporter, sodium-dependent noradrenaline transporter, and sodium-dependent dopamine transporter. In addition, it is known to target G protein-activated inward rectifier potassium channel 2, muscarinic acetylcholine receptor M2, potassium voltage-gated channel subfamily H member 1, and G protein-activated inward rectifier potassium channel 4.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
---|---|
mental disorders | D001523 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Trimipramine maleate
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
SURMONTIL | Odyssey Pharmaceuticals | N-016792 DISCN | 1982-01-01 | 3 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
trimipramine maleate | ANDA | 2023-06-14 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
depressive disorder | EFO_1002014 | D003866 | F32.A |
psychotic affective disorders | — | D000341 | F39 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
169 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hiv infections | D015658 | EFO_0000764 | B20 | 3 | 6 | 14 | 4 | 5 | 30 |
Pneumocystis pneumonia | D011020 | EFO_0007448 | B59 | 1 | 4 | 12 | 3 | 2 | 20 |
Urinary tract infections | D014552 | EFO_0003103 | N39.0 | — | 3 | 5 | 7 | 4 | 19 |
Infections | D007239 | EFO_0000544 | 1 | 2 | 2 | 3 | 1 | 8 | |
Malaria | D008288 | EFO_0001068 | B54 | — | — | 7 | 1 | — | 8 |
Methicillin-resistant staphylococcus aureus | D055624 | — | 2 | 1 | 1 | 1 | 5 | ||
Pneumonia | D011014 | EFO_0003106 | J18 | — | 1 | 4 | 1 | — | 5 |
Tuberculosis | D014376 | EFO_0000774 | A15-A19 | — | 2 | 2 | 1 | — | 4 |
Hiv | D006678 | O98.7 | — | — | 1 | 2 | — | 3 | |
Bacteriuria | D001437 | R82.71 | 1 | 1 | — | 1 | — | 3 |
Show 26 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Bacterial infections | D001424 | A49 | 5 | 1 | 1 | — | 1 | 8 | |
Abscess | D000038 | EFO_0003030 | — | — | 2 | — | 4 | 6 | |
Sepsis | D018805 | A41.9 | — | 1 | 3 | — | — | 4 | |
Staphylococcal infections | D013203 | A49.01 | — | 2 | 3 | — | — | 4 | |
Mycoses | D009181 | B35-B49 | 1 | — | 1 | — | — | 2 | |
Pneumocystis | D011010 | — | — | 2 | — | — | 2 | ||
Idiopathic pulmonary fibrosis | D054990 | J84.112 | — | — | 2 | — | — | 2 | |
Multiple myeloma | D009101 | C90.0 | — | 1 | 1 | — | — | 2 | |
Vesico-ureteral reflux | D014718 | EFO_0007536 | N13.7 | — | — | 2 | — | — | 2 |
Osteomyelitis | D010019 | EFO_0003102 | M86 | — | — | 1 | — | 1 | 2 |
Show 16 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Lymphoma | D008223 | C85.9 | 1 | 3 | — | — | 1 | 4 | |
Cystic fibrosis | D003550 | EFO_0000390 | E84 | — | 3 | — | — | — | 3 |
Sinusitis | D012852 | EFO_0007486 | J32 | — | 1 | — | — | 1 | 2 |
Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | 1 | — | — | 1 | 2 |
Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | 1 | — | — | 1 | 2 |
Neoplasms | D009369 | C80 | 2 | 1 | — | — | — | 2 | |
Staphylococcus aureus | D013211 | NCBITaxon_1280 | — | 1 | — | — | 1 | 2 | |
Leukemia | D007938 | C95 | 1 | 2 | — | — | — | 2 | |
Kidney diseases | D007674 | EFO_0003086 | N08 | 2 | 2 | — | — | — | 2 |
Kidney transplantation | D016030 | 2 | 2 | — | — | — | 2 |
Show 21 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Bronchitis | D001991 | J40 | — | — | — | — | 3 | 3 | |
Hypospadias | D007021 | EFO_0004209 | Q54 | — | — | — | — | 2 | 2 |
Delirium | D003693 | R41.0 | — | — | — | — | 1 | 1 | |
Ulcerative colitis | D003093 | EFO_0000729 | K51 | — | — | — | — | 1 | 1 |
Non-hodgkin lymphoma | D008228 | C85.9 | — | — | — | — | 1 | 1 | |
Pregnancy complications | D011248 | — | — | — | — | 1 | 1 | ||
Urolithiasis | D052878 | N20-N23 | — | — | — | — | 1 | 1 | |
Bacterial skin diseases | D017192 | — | — | — | — | 1 | 1 | ||
Cellulitis | D002481 | EFO_0003035 | L03.90 | — | — | — | — | 1 | 1 |
Diabetic foot | D017719 | EFO_1001459 | — | — | — | — | 1 | 1 |
Show 4 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | TRIMIPRAMINE |
INN | trimipramine |
Description | Trimipramine is a dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)-2-methylpropyl group at the nitrogen atom. It is used as an antidepressant. It has a role as an antidepressant, an environmental contaminant and a xenobiotic. It is a dibenzoazepine and a tertiary amino compound. It is functionally related to an imipramine. |
Classification | Small molecule |
Drug class | antidepressants (imipramine type) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CC(CN(C)C)CN1c2ccccc2CCc2ccccc21 |
Identifiers
PDB | — |
CAS-ID | 739-71-9 |
RxCUI | 10834 |
ChEMBL ID | CHEMBL644 |
ChEBI ID | 9738 |
PubChem CID | 5584 |
DrugBank | DB00726 |
UNII ID | 6S082C9NDT (ChemIDplus, GSRS) |
Target
Agency Approved
SLC6A4
SLC6A4
SLC6A2
SLC6A2
SLC6A3
SLC6A3
Organism
Homo sapiens
Gene name
SLC6A4
Gene synonyms
HTT, SERT
NCBI Gene ID
Protein name
sodium-dependent serotonin transporter
Protein synonyms
5-hydroxytryptamine (serotonin) transporter, 5HT transporter, 5HTT, Na+/Cl- dependent serotonin transporter, serotonin transporter 1, solute carrier family 6 (neurotransmitter transporter), member 4, solute carrier family 6 (neurotransmitter transporter, serotonin), member 4, Solute carrier family 6 member 4
Uniprot ID
Mouse ortholog
Slc6a4 (15567)
sodium-dependent serotonin transporter (Q60857)
Alternate
KCNJ6
KCNJ6
CHRM2
CHRM2
KCNH1
KCNH1
KCNJ5
KCNJ5
Organism
Homo sapiens
Gene name
KCNJ6
Gene synonyms
GIRK2, KATP2, KCNJ7
NCBI Gene ID
Protein name
G protein-activated inward rectifier potassium channel 2
Protein synonyms
BIR1, Inward rectifier K(+) channel Kir3.2, inward rectifier potassium channel KIR3.2, KATP-2, Potassium channel, inwardly rectifying subfamily J member 6, potassium channel, inwardly rectifying subfamily J, member 6, potassium voltage-gated channel subfamily J member 6
Uniprot ID
Mouse ortholog
Kcnj6 (16522)
G protein-activated inward rectifier potassium channel 2 (P48542)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,410 documents
View more details
Safety
Black-box Warning
Black-box warning for: Trimipramine maleate
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
35,556 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more